Related Experiment Videos
Insights
Heart failure, often caused by heart disease or damage, remains a terminal condition. Despite treatment advances, its high mortality rate rivals that of many cancers.
Area of Science:
- Cardiology
- Internal Medicine
- Oncology
Background:
- Heart failure (HF) is a complex clinical syndrome frequently stemming from underlying conditions like coronary heart disease, valvular disease, hypertension, or cardiomyopathy.
- Extensive myocardial damage following multiple heart attacks can precipitate the development of heart failure.
- Despite significant progress in cardiovascular disease management, chronic heart failure presents a grim prognosis, comparable to that of numerous malignant tumors.
Purpose of the Study:
- To review the origins and prognosis of heart failure.
- To highlight the severity of chronic heart failure in comparison to malignant tumors.
Main Methods:
- Literature review of heart failure etiology and outcomes.
- Comparative analysis of mortality rates for heart failure and various cancers.
Main Results:
- Identified coronary heart disease, valvular disease, hypertension, and cardiomyopathy as primary causes of heart failure.
- Demonstrated that heart failure can develop subsequent to myocardial damage from events like heart attacks.
- Established that chronic heart failure carries a mortality rate similar to many malignant tumors.
Conclusions:
- Heart failure necessitates comprehensive management strategies due to its severe origins and progression.
- The terminal nature and high death rate of chronic heart failure underscore the urgent need for further research and therapeutic advancements.
Abstract:
Heart failure usually originates from conditions such as coronary heart disease, valvular disease, hypertension or cardiomyopathy. Heart failure may develop after several heart attacks as a result of extensive myocardial damage. Despite many advances in treatment for heart disease, chronic heart failure is a terminal condition with a death rate as high as that for many malignant tumours.